Por favor, use este identificador para citar o enlazar este ítem: https://www.arca.fiocruz.br/handle/icict/58929

Tipo
Artículo
Derechos de autor
Acceso abierto
Colecciones
Compartir

Estadísticas
Metadatos
Mostrar el registro completo del ítem

SELECTIVE OR UNIVERSAL HEPATITIS B BIRTH DOSE IN SUB-SAHARAN AFRICA?
Lewis-Ximenez, Lia-Laura et al. | Fecha del documento: 2023
Autor
Lewis-Ximenez, Lia-Laura
Peliganga, Luis Baião
Afiliación
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Ambulatório de Hepatites Virais. Rio de Janeiro, RJ, Brasil.
Ministério da Saúde de Luanda. Universidade Agostinho Neto. Faculdade de Medicina. Departamento de Investigação de Medicina Interna. Luanda, Angola.
Palabras clave en portugues
Dose seletiva ou universal para hepatite B
África Subsaariana
Crianças nascidas de mães positivas para o antígeno de superfície da hepatite B (HBsAg)
Ou aqueles cujas mães não foram testadas para infecção pelo vírus da hepatite B (HBV).
 
Palabras clave en ingles
Selective or Universal hepatitis B dose
Sub-Saharan Africa
Infants born to hepatitis B surface antigen (HBsAg)-positive mothers
Or those whose mothers were not tested for hepatitis B virus (HBV) infection.
 
Editor
The Lancet
Referencia
LEWIS-XIMENEZ, Lia Laura; PELIGANGA, Luis Baião. Selective or universal hepatitis B birth dose in sub-Saharan Africa?. The Lancet, v. 11, p. 1-2, May 2023.
ISSN
1474-547X
Notas
Afifa Ansar and colleagues1 in The Lancet Global Health suggest targeting the hepatitis B birth dose (HepB-BD) in sub-Saharan Africa to only infants born to hepatitis B surface antigen (HBsAg)-positive mothers or those whose mothers were not tested for hepatitis B virus (HBV) infection. This suggestion is based on a systematic review and meta-analysis by the authors in which they did not find a statistical difference for the risk of infant HBV infection when mothers were HBV negative, whether infants received a birth dose (HepB-BD) or a first dose of hepatitis B vaccine only at age 6 weeks. We would like to suggest that these results are not sufficient to revise the current WHO universal Hep-BD vaccine recommendation........